Arthritis Clinical Trials in Cincinnati

View 33 new treatments for Arthritis in Cincinnati, OH near me. Every day, Power helps hundreds of Arthritis patients connect with leading medical research.
View 30 trials in Cincinnati
Filter (30)

Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis

Eli Lilly Clinic, Cincinnati + 1 more

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Adalimumab Discontinuation for Uveitis

Research Clinic, Cincinnati + 1 more

The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).Show More
Waitlist
Phase 4
Est. 3 - 6 Weeks
Nisha Acharya, MD MS
Principal Investigator

Baricitinib for Rheumatoid Arthritis

Eli Lilly Clinic, Cincinnati + 1 more

This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, Dayton + 2 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
David W Romness, MD
Principal Investigator

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, Cincinnati + 1 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Upadacitinib for Axial Spondyloarthritis

AbbVie Clinic, Springboro + 1 more

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director

Tildrakizumab SC Injection for Psoriatic Arthritis

Sun Clinic, Cincinnati + 1 more

An open label phase 3 study
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Blue Ash + 3 more

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director

Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis

Research Clinic, Liberty Township + 1 more

This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Jasvinder Singh, MD
Principal Investigator

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Springboro + 1 more

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 3

Frequently Asked Questions

How much do arthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do arthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across arthritis trials in Cincinnati, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for arthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Cincinnati is research being conducted for arthritis?

Cincinnati Children's Hospital Medical Center is a prominent location conducting arthritis clinical trials in Cincinnati, with approximately 10 trials ongoing as of 2023. These trials are concentrated in the central area of the city.

What promising new drugs are being tested?

In Cincinnati, arthritis research is focusing on treatments like Monoclonal Antibodies, TNF Inhibitors, and Janus Kinase (JAK) Inhibitors. Notable specific interventions being studied include Tildrakizumab, Baricitinib, and Adalimumab.